THE SIXTEENTH ANNUAL
Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum

CO CHAIRS:
- Matthew D’Ambrosio, MBA, JD, Senior Vice President, Chief Compliance and Ethics Officer, Sunovion Pharmaceuticals Inc.
- Gary Del Vecchio, Executive Director, US Pharmaceutical Compliance and Ethics, Bristol-Myers Squibb Company
- Elizabeth Jobes, Esq., Head of Corporate Compliance and Legal Counsel, Spark Therapeutics

KEYNOTE SPEAKERS:
- Thomas W. Abrams, RPh, MBA, Director, Office of Prescription Drug Promotion, Food and Drug Administration
- Robert Barrington, PhD, Executive Director, Transparency International-UK
- Douglas Brown, Deputy Director, Data Sharing and Partnership Group, Center for Program Integrity, Centers for Medicare and Medicaid Services, US Department of Health and Human Services
- Benjamin C. Mizer, Esq., Principal Deputy Assistant Attorney General and Head of the Civil Division, US Department of Justice
- Mary E. Riordan, Esq., Senior Counsel, Office of Counsel to the Inspector General, Office of Inspector General, US Department of Health and Human Services
- Jeffrey S. Sallet, National Chief of Public Corruption and Civil Rights, Federal Bureau of Investigation

CO CHAIRS:
TRANSFORMATIONAL LEARNING — EFFECTIVE KNOWLEDGE EXCHANGE

MEDIA PARTNERS:
- LSC Life Science Compliance
- Harvard Health Policy Review
- Health Affairs

GOLD GRANTOR:
- Huron Life Sciences

SILVER GRANTORS:
- Deloitte
- Navigant Life Sciences
- BDO
- pwc

BRONZE GRANTORS:
- AlixPartners
- ARNOLD & PORTER LLP
- Cooley LLP
- Davis Wright Tremaine LLP
- Grant Thornton
- HealthCare Appraisers Inc.
- imshealth
- King & Spalding
- Paul Hastings
- Polaris
- Porzio LifeSciences
- Ropes & Gray
- Skadden

CONTINUING EDUCATION CREDITS:
Accounting Professionals: Approved for up to 16 NASBA CPE credits.
Compliance Professionals: The Congress is currently pending approval to offer Compliance Certification Board CCB Credits.
Attorneys: The Congress is currently pending approval to offer California, Pennsylvania and Texas MCLE Credit.

www.PharmaCongress.com
Onsite:
October 21 – 23, 2015
Washington, DC

SPECIAL PCF REGISTRATION DISCOUNTS — See page 11.

SPONSOR:
THE PHARMACEUTICAL COMPLIANCE FORUM

A Hybrid Conference & Internet Event
See page 2
Webcast: In your own office or home live via the Internet with 24/7 access for six months
INVITATION TO ATTEND THE PCF PHARMA CONGRESS

As the new Vice President, Pharma and Medical Device Content, Global Health Care — Life Sciences, LLC, it is my pleasure to invite you to attend the 2015 Sixteenth Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum sponsored by the PCF. This year’s Congress will feature presentations by leading government regulators, company compliance professionals, in-house counsel, prominent industry consultants and legal counsel. Please plan to join me and the Planning Committee for three stimulating days of continuing education, networking and best practice sharing.

ABOUT THE CONGRESS SPONSOR

The Pharmaceutical Compliance Forum (PCF) is a coalition of senior compliance professionals and legal counsel from more than 50 of the largest research-based pharmaceutical manufacturers. The PCF was founded in early-1999 by compliance professionals from the pharmaceutical industry to promote effective corporate compliance programs. The members meet twice a year, for two days, focusing on open and informal sharing of compliance information, best practices, and current developments in the field. PCF also sponsors this three-day compliance congress each Fall. For membership information, contact Kelly Freeman via email at kelfreem@gmail.com. Please visit their website at www.PharmaComplianceForum.org.

AGENDA AT A GLANCE

Wednesday, October 21, 2015

7:30 am Congress Registration

8:00 am – 11:30 am PRECONFERENCE SYMPOSIA (Optional, Choose only one):

Precon I: Regulatory Concepts: Basic Principles
Precon II: Innovations in Risk Assessment, Auditing and Monitoring
Precon III: Advanced Issues in Domestic and Global Transparency . . .
Precon IV: Advanced Global Compliances Issues

OPENING PLENARY SESSION

1:00 pm Welcome and Introduction: PCF Co-Chairs
1:15 pm Keynote: OIG Update
2:00 pm AUSA Panel
2:45 pm FBI’s New Focus on FCPA Investigations
3:15 pm Break
3:45 pm Keynote: FDA-OPDP Update
4:15 pm Chief Compliance Officer Roundtable
5:00 pm Panel: FCPA Anticorruption: Examining a Hypothetical Case from All Sides: DOJ, SEC, and COO
4:55 pm ADDJOURNMENT AND NETWORKING RECEPTION

Thursday, October 22, 2015

7:00 am Registration Opens; Continental Breakfast in Exhibit Hall

MORNING PLENARY SESSION

8:00 am Welcome and Introductions
8:15 am US DOJ Civil Section Update
8:45 am Keynote: Transparency International’s New Pharma Industry Initiative
9:15 am Qui Tam Panel
10:00 am Recent Developments in the Debate over Off-Label Communications and the First Amendment
10:30 am Networking Break
11:00 am – 12:00 pm MINI SUMMITS BLOCK A

MS I: Managing Speaker Program Compliance . . .
MS II: R&D: Compliance . . .
MS III: Business Development Part 1 . . .
MS IV: Evaluating Compliance Program Effectiveness . . .
MS V: Providers Part 1 . . .
MS VI: Patient Support Programs Part 1 . . .

12:00 pm NETWORKING LUNCHEON

1:15 pm – 2:15 pm MINI SUMMITS BLOCK B

MS VII: Predictive Analytics
MS VIII: Coordinating Risk Management . . .
MS IX: Managing Multi-National HCP Meetings . . .
MS X: Business Development Part 2 . . .
MS XI: Public Disclosures . . .
MS XII: Patient Support Programs Part 2 . . .

2:15 pm Transition Break

2:30 pm – 3:30 pm MINI SUMMITS BLOCK C

MS XIII: Innovation in Training and Communications
MS XIV: Compliance Considerations . . .
MS XV: New Product Launches . . .
MS XVI: Business Development Part 3 . . .
MS XVII: Marketing and Medical Affairs . . .
MS XVIII: Structuring Specialty Pharmacy Distribution . . .
MS XIX: Payers and Providers Part 2 . . .

3:30 pm Networking Break

CLOSING PLENARY SESSION

4:00 pm Update from CMS on Open Payments
4:30 pm Consolidation, Vertical Integration and Cross-Border Business
5:15 pm Millennials and the Future of Ethics and Compliance Programs
6:30 pm Adjournment

Friday, October 23, 2015: INDUSTRY-ONLY COMPLIANCE BEST PRACTICES THINK TANK, 8:30 am – Noon

PARTICIPATION OPTIONS

TRADITIONAL ONSITE ATTENDANCE

Simply register, travel to the conference city and attend in person.

PROS: subject matter immersion; professional networking opportunities; faculty interaction.

LIVE AND ARCHIVED INTERNET ATTENDANCE

Watch the conference in live streaming video over the Internet and at your convenience at any time 24/7 for six months following the event.

The archived conference includes speaker videos and coordinated PowerPoint presentations.

PROS: Live digital feed and 24/7 Internet access for the next six months; accessible in the office, at home or anywhere worldwide with Internet access; avoid travel expense and hassle; no time away from the office.

WHO SHOULD ATTEND:

- Pharmaceutical and Health Care Executives and Board Members
- Compliance Executives
- Health Plan, Health System and Physician Organizations
- Medical Directors
- Physicians
- Pharmacists and Pharmacy Technicians
- Purchasers, including Private Employers and Public Purchasers
- Pharmaceutical Manufacturers
- Generic Pharmaceutical Manufacturers
- Site Management Organizations
- Clinical Research Organizations
- Pharmacy Benefit Management Companies
- Nurses
- Health Plans and Insurers
- Wholesale, Retail, Mail Order and Internet Pharmacies
- Health Care Attorneys and In-house Counsel
- Compliance Officers
- Privacy Officers
- Ethics Officers
- Food and Drug Law Attorneys
- Pharmaceutical Consultants
- Investment Bankers
- Venture Capitalists
- Health Care Regulators and Policy Makers
- Health Services Researchers and Academics
- Auditors
Preconference II: Innovations in Risk Assessment, Auditing and Monitoring

8:00 am Welcome and Overview
Lori Alarimo, JD, Director, Healthcare and Life Sciences Disputes, Regulatory, Compliance and Investigations, Navigant Consulting, Inc., Irvine, CA (Moderator)

8:10 am Incorporating Effective Record Reviews In Your Auditing & Monitoring Plan
Chris Castro, CCEP, Associate Director, Healthcare and Life Sciences Disputes, Regulatory, Compliance and Investigations, Navigant Consulting, Inc., Phoenix, AZ

8:50 am Enhancing Sales Performance through Field Based Monitoring
Kerry Clem, Senior Vice President, Sales, Acorda Therapeutics, Ardsley, NY
Wendy Heckelman, PhD, President and Founder, WLH Consulting, Inc., Fort Lauderdale, FL

9:30 am Break

9:45 am Getting Ahead of the Game — Utilizing Data and Other Operational Indicators to Identify Potential Compliance Issues Early
Gary Keilty, Managing Director, FTI, Washington, DC

10:30 am Building a Compliance Data Analytics Capability
Amy Pawloski, CPA, CCEP, Head of US Compliance & Ethics Monitoring and Data Analytics, Bristol-Myers Squibb, Plainsboro, NJ

11:00 am Effective Field Monitoring Essentials to Consider when Working with Sales, Marketing and Medical Teams
Scot Steinheiser, CHC, CCEP, Managing Partner and Founder, Commercial Compliance Consulting, SCS Compliance Group LLC, Mundelein, IL
Gary Mendelson, Assistant Director, Corporate Compliance for Oncology, Astellas, Greer, SC

11:30 am Preconference Adjournment

Preconference III: Advanced Issues in Domestic and Global Transparency and Analytics: Taking the Data to the Next Level

8:00 am Welcome and Overview
Edward Glynn, MBA, Principal, Ernst & Young LLP, New York, NY (Moderator)

8:10 am Exploring the Analytics Maturity Model: Capitalizing on your Investment in Aggregate Spend
Corey Dunbar, CFE, Senior Manager, Fraud Investigations & Dispute Services, Ernst & Young LLP, New York, NY

8:50 am Linking Aggregate Spend Data with Other Data Sources to Identify Compliance Trends, Learn about your Competitors and Provide Strategic Insights to the Business
Véronique Monjardet, PhD, Country Manager – France, Pularis, Paris, France

9:30 am Break

9:50 am Advanced Analytics: The Art of the Possible in Providing Value-Added Insights to the Business
Samir Hans, MS, Principal, Deloitte, Washington, DC

10:30 am Using Company-specific and Open Payments Data to Ensure Accuracy and Gain Insights
Terrell Sweat, MBA, Compliance Director, Actelion Pharmaceuticals, South San Francisco, CA
Jonathan Wikenfeld, MBA, President, Potomac River Partners, Vienna, VA

11:00 am Growing and Integrating Global Transparency Analytics
Nadeem “Ned” Mumtaz, MBA, MIS, Practice Leader and Associate Partner, Streebo Inc., Princeton, NJ
Dr. Seth B. Whitelaw, President and CEO, Whitelaw Compliance Group, LLC, West Chester, PA

11:30 am Preconference Adjournment

Preconferences Continued on page 4
PHARMA CONGRESS: AGENDA DAY I
OPENING PLENARY SESSION

1:00 pm Welcome and Introduction: PCF Co-Chairs
Matthew D’Ambrosio, JD, MBA, Senior Vice President, Chief Compliance and Ethics Officer, Sunovion Pharmaceuticals, Inc., Marlborough, MA (Co-chair)
Gary Del Vecchio, Executive Director, US Pharmaceutical Compliance and Ethics, Bristol-Myers Squibb Company, Plainsboro, NJ (Co-chair)
Elizabeth V. Jobes, Esq., Head of Corporate Compliance and Legal Counsel, Spark Therapeutics, Philadelphia, PA (Co-chair)

Keynote: OIG Update
Mary E. Riordan, Esq., Senior Counsel, Office of Counsel to the Inspector General, Office of Inspector General, Department of Health and Human Services, Washington, DC

Introduction by Matthew D’Ambrosio, JD, MBA, Senior Vice President, Chief Compliance and Ethics Officer, Sunovion Pharmaceuticals, Inc., Marlborough, MA (Co-chair)

AUSA Panel
M. Beth Leahy, Esq. (Invited), Assistant US Attorney, United States Attorney’s Office, Eastern District of Pennsylvania, Philadelphia, PA
Richard Robinson, Esq. (Invited), Section Chief-Major Frauds, Criminal Division, United States Attorney’s Office, Central District of California, Los Angeles, CA
K. Nathaniel Yeager, Esq., Chief, Health Care Fraud Unit, United States Attorney’s Office, District of Massachusetts, Boston, MA
John T. Bentivoglio, Esq., Partner, Skadden Arps LLP; Former Special Counsel for Healthcare Fraud and Chief Privacy Officer, US Department of Justice, Washington, DC (Moderator)

HOTEL INFORMATION/RESERVATIONS

The Mandarin Oriental is the official hotel for the SIXTEENTH PHARMACEUTICAL REGULATORY AND COMPLIANCE CONGRESS. A special group rate of $300.00 Deluxe Room per night (plus tax) has been arranged for Congress Attendees.

To make your hotel reservations online please go to www.PharmaCongress.com and click on the Travel/Hotel tab. You can also make reservations by calling the Mandarin Oriental directly at (202) 787-6140 or Toll Free (888) 888-1778. Please ask for the Pharma Congress Group Rate when you call.

Reservations at the group rate will be accepted while rooms are available or until the cut-off date of Tuesday, September 29, 2015. After this date, reservations will be accepted on a space-available basis at the prevailing rate.

The Pharmaceutical Compliance Congress does not contract with any third party organization to make hotel reservations for attendees of the Congress. All attendees should make their hotel reservations directly with the hotel and not with a third party vendor.

Mandarin Oriental • 1330 Maryland Avenue SW • Washington, DC 20024
THURSDAY, OCTOBER 22, 2015

PHARMA CONGRESS: AGENDA DAY II

7:00 am  Registration Opens; Continental Breakfast in Exhibit Hall

MORNING PLENARY SESSION

8:00 am  Welcome and Introductions

Elizabeth V. Jobes, Esq., Head of Corporate Compliance and Legal Counsel, Spark Therapeutics, Philadelphia, PA (Co-chair)

US DOJ Civil Section Update

Benjamin Nizer, Esq., Principal Deputy Assistant Attorney General and Head of the Civil Division, US Department of Justice; Former Counselor to Attorney General Eric H. Holder, Jr, Washington, DC

Introduction by Michael K. Loucks, Esq., Partner, Skadden Arps LLP; Former Acting United States Attorney, US Attorney’s Office for the District of Massachusetts, Washington, DC

8:45 am  Keynote: Transparency International’s New Pharma Industry Initiative

Robert Barrington, PhD, Executive Director, Transparency International-UK, London, UK

Introduction by Jack Tanselle, MBA, Managing Director, Navigant Consulting, Inc., Indianapolis, IN

9:15 am  Qui Tam Panel

Jillian Estes, Esq., Partner, James Hoyer Newcomer & Smiljanich, PA; Former Attorney, International Division, National Center for Missing and Exploited Children, Tampa, FL

Loren Jacobson, Esq., Partner, Waters & Kraus LLP, Dallas, TX

Joseph Trautwein, Esq., Joseph Trautwein & Associates LLC; Former Assistant US Attorney, Eastern District of Pennsylvania, Philadelphia, PA

Jonathan Diesenhaus, Esq., Partner, Hogan Lovells LLP; Former Senior Trial Counsel, Fraud Section, Civil Division, US Department of Justice, Washington, DC (Moderator)

10:00 am  Recent Developments in the Debate over Off-Label Communications and the First Amendment

Paul E. Kalb, JD, MD, Partner and Global Coordinator, Life Sciences Practice, Sidley Austin LLP; Washington, DC

Introduction by Gary Del Vecchio, Executive Director, US Pharmaceutical Compliance and Ethics, Bristol-Myers Squibb Company, Plainsboro, NJ (Co-chair)

10:30 am  Networking Break
MINI SUMMITS BLOCK A 11:00 am – 12:00 pm
Mini Summit I: Managing Speaker Program Compliance: Benchmarking and Best Practices
Gregory Beeman, Lilly USA Ethics and Compliance Officer, Eli Lilly and Company, Indianapolis, IN
Ronni E. Fuchs, Esq., Partner, Pepper Hamilton LLP, Princeton, NJ
Raymond S. Wysmierski, MBA, MUP, Associate Director, Compliance, Avanir Pharmaceuticals, Inc., Aliso Viejo, CA
Katherine Buckley, MBA, Principal, Pharmaceutical and Life Sciences Advisory Practice, PwC, Philadelphia, PA (Moderator)

Mini Summit II: R&D Compliance: Prepare Now for Future Enforcement
Dennis K. Barnes, JD, MBA, CPA, Vice President, Chief Compliance Officer, PAREXEL International, Waltham, MA
Paul Curtin, JD, CFE, Executive Director, R&D Compliance, Allergan; Former Head of Compliance - Ex-US, Forest Laboratories, Jersey City, NJ
Daniel A. Kracov, Esq., Partner and Head, FDA and Healthcare Practice, Arnold & Porter, Washington, DC
George K. Ng, Esq., Executive Vice President & Chief Legal Officer, Sorrento Therapeutics, Inc., San Diego, CA
Yogesh Bahl, CPA, MBA, Managing Director, AlixPartners, New York, NY (Moderator)

Mini Summit III: Business Development Part 1: Mergers and Acquisitions — Preparing to be Acquired and Pre-Deal Due Diligence
Timothy Ayers, JD, MPH, Vice President, Chief Compliance Officer, Horizon Pharma plc; Former Vice President, Chief Compliance Officer, Dendreon, Chicago, IL
Justin Dillon, Senior Director - Compliance, Auditing & Monitoring, Incyte, Wilmington, DE
Michael B. Dusseau, Vice President, Compliance Operations, Allergan plc; Former Vice President, Compliance, Bayer, Parsippany, NJ
William L. Intner, Esq., Partner, Hogan Lovells LLP, Baltimore, MD
Virginia “Ginny” A. Gibson, Esq., Partner, Hogan Lovells LLP; Former Executive Assistant U.S. Attorney, Eastern District of Pennsylvania, Philadelphia, PA (Moderator)

Mini Summit IV: Evaluating Compliance Program Effectiveness — Board Responsibilities, Board Advisors, and Compliance Experts
Thomas E. Costa, Esq., Compliance Consultant; Former Vice President, US Pharmaceuticals Compliance, Bristol-Myers Squibb, Yardley, PA
Christopher Fletchall, MBA, Senior Director, Ethics and Compliance, Eli Lilly and Company, Indianapolis, IN
Lawrence P. Platkin, Vice President and Head, U.S. Compliance Center of Excellence, Bayer Corporation, Whippany, NJ
Keith M. Korenchuk, JD, MPH, Partner, Arnold & Porter LLP, Washington, DC (Moderator)

Chris Cobourn, Managing Director, Huron Consulting Group, New York, NY
Alessandra Hawthorne, Esq., Vice President, Chief Ethics and Compliance Officer, Boehringer-Ingelheim Pharmaceuticals, Ridgefield, CT
Jeffrey Rosenbaum, MBA, Senior Vice President, Chief Compliance and Risk Officer, Shire; Former Chief Compliance Officer, Vertex Pharmaceuticals, Lexington, MA
Brian Riewerts, MPA, Partner, Global Pharmaceuticals and Life Sciences, PwC, Philadelphia, PA (Moderator)

Mini Summit VI: Patient Support Programs Part 1: Getting Closer to the Patient
Thomas M. Glavin, Esq., Vice President, Deputy Compliance Officer, Shire, Philadelphia, PA
Stephen M. Lawniczak, Esq., Senior Counsel, AbbVie, Chicago, IL
Aliison Fethke, Esq., Counsel, Health Care Group, Ropes & Gray, Chicago, IL (Moderator)

MINI SUMMITS BLOCK B 1:15 pm – 2:15 pm
Mini Summit VII: Predictive Analytics
John Patrick Oroho, Esq., Executive Vice President and Chief Strategy Officer, Porzio Life Sciences, LLC; Principal, Porzio Bromberg & Newman, PC, Morristown, NJ
Mark Linver, MS, Managing Director, Huron Consulting Group, New York, NY (Moderator)

Mini Summit VIII: Coordinating Risk Management across the Control Functions: Audit, Compliance, Finance, Legal, Regulatory and Quality — An Opportunity to Leverage Technology
John Conrad, Principal, Deloitte, Philadelphia, PA

Mini Summit IX: Managing Multi-National HCP Meetings: Complying with the Codes and Transparency Requirements
Jodie Dillon, MPH (Invited), Head, External Interface Office, AstraZeneca, New York, NY
Tali Guy, Esq., Senior Director, Global R&D Compliance Officer, Teva Pharmaceutical Industries Ltd, Petah Tikva, Israel
Marc Eigner, MBA, MS, Senior Partner and Co-Founder, Polaris, New York, NY (Moderator)

Mini Summit X: Business Development Part 2: Mergers and Acquisitions — Post-Deal Due Diligence and Integration Challenges
Corey R. Amundson, Esq., First Assistant United States Attorney and Chief, Criminal Division, United States Attorney’s Office, Middle District of Louisiana, Baton Rouge, LA
Jeffrey L. Handwerker, Esq., Partner, Arnold & Porter LLP, Washington, DC
Mark A. Jensen, Esq., Partner, Special Matters and Government Investigations Team, King & Spalding, Washington, DC
Joanne Lahner, Esq., Vice President, GH1 Compliance, Merck & Co., Inc., North Wales, PA
Maureen McGrir, Esq., Vice President, Office of Ethics, Global Compliance Organization, Merck & Co., Inc., Kenilworth, NJ (Moderator)

Mini Summit XI: The Impact of Public Disclosures on Operations and Processes within Life Science Organizations
Michael O’Connor, MS, Senior Director, Compliance and Ethics, Alexion Pharmaceuticals, Inc., Cheshire, CT
Gus Papandrikos, MBA, Senior Director, Compliance, Daiichi Sankyo, Parsippany, NJ
William Buzzee, MS, General Manager, US Compliance, IMS Health, Plymouth Meeting, PA (Moderator)

Mini Summit XII: Patient Support Programs Part 2: Patient Services: Privacy and Pharmacovigilance Considerations
William Greenrose, MA, MBA, Director, Advisory - Governance Regulatory and Risk Strategies Practice, Deloitte & Touche, LLC, Boston, MA
Megan Mikkelson, CIPP/US, CHIPS, Director, US Chief Privacy Officer, Teva Pharmaceuticals, Kansas City, MO
Terra L. Reynolds, Esq., Of Counsel, Litigation Department, Paul Hastings LLP; Former Assistant U.S. Attorney, Northern District of Illinois, Chicago, IL
Stephanie Wisdo, Esq., Corporate Attorney, Otsuka America Pharmaceutical, Inc., Princeton, NJ
Regina Gore Cavaliere, Esq., Principal, Advisory, KPMG; Former Vice President and Chief Compliance Officer, Otsuka America Pharmaceutical, Inc., Short Hills, NJ (Moderator)

2:15 pm Transition Break

EXHIBIT AND SPONSORSHIP OPPORTUNITIES
Take advantage of this unique opportunity to expand your reach! The Congress is attended by highly influential and experienced professionals. Sponsorship offers you strategic positioning as an industry leader. For more information call 206-673-4815 or email exhibits@hcconferences.com.
MINI SUMMITS BLOCK C  2:30 pm – 3:30 pm

Mini Summit XII: Innovation in Training and Communications
Jayson Dukes, Senior Managing Director, FTI, New York, NY
Margaret K. Feltz, MA, JD, Executive Director, Corporate Compliance, Purdue Pharma LP; Former Member, PCF Executive Committee, Stamford, CT
Matthew Ruble, MS, Senior Manager, Grant Thornton, Philadelphia, PA (Moderator)

Mini Summit XIV: Compliance Considerations when Evaluating Non-Traditional HCP Compensation Arrangements: Royalties, Stock Options, and Licensing Agreements
Stuart A. Neiberg, MAcc, CPA, CFA, Director, HealthCare Appraisers, Delray Beach, FL
Lee H. Rosebush, JD, PharmD, MS, MBA, Pharmacy Team Leader and FDA Partner, Baker & Hostetler LLP, Washington DC
Ann S. Brandt, PhD, Partner, HealthCare Appraisers, Inc., Delray Beach, FL (Moderator)

Mini Summit XV: New Product Launches and the Pre-Launch Period — Strengthening the Partnership with the Business
Terri Ledva, MS, Senior Manager Compliance, Iroko Pharmaceuticals LLC, Philadelphia, PA
Kari Loeser, Esq., Senior Counsel, Jazz Pharmaceuticals, Palo Alto, CA
Fernando Villegas, MS, Director, Oncology Marketing, Jazz Pharmaceuticals, Palo Alto, CA
Kelly N. “Nikki” Reeves, MPA, JD, Partner, King & Spalding LLP; Legal Counsel, Ad Hoc Sunshine and State Law Compliance Group, Washington, DC (Moderator)

Mini Summit XVI: Business Development Part 3: Joint Ventures and Co-Promotion Arrangements
Kathleen Hamill, Esq., Assistant General Counsel, Johnson & Johnson, Philadelphia, PA
Kellie Combs, Esq., Counsel, Ropes & Gray, Washington, DC (Moderator)

Mini Summit XVII: Marketing and Medical Affairs: Where is the Line in the Sand?
Mark A. DeWyngaert, MBA, PhD, Managing Director, Huron Consulting Group, New York, NY (Moderator)

Mini Summit XVIII: Structuring Specialty Pharmacy Distribution Arrangements in a Turbulent Regulatory Environment
Thomas Beimers, Esq., Healthcare, Compliance, and Government Investigations Attorney at Faegre Baker Daniels LLP, Minneapolis, MN
John “Jack” S. Linehan, Esq., Healthcare Attorney, Epstein Becker & Green, Washington, DC (Moderator)

Mini Summit XIX: Payers and Providers Part 2: Value Propositions in Contractual Relationships — Real World Evidence, Outcomes Research, and Comparative Effectiveness
Kathleen Peterson, Esq., Special Counsel, Cooley LLP, Washington, DC
BJ D’Avella, MBA, Senior Director, Huron Consulting Group, New York, NY (Moderator)

3:30 pm    Networking Break

CLOSING PLENARY SESSION

4:00 pm    Update from CMS on Open Payments
Douglas Brown, Deputy Director, Data Sharing & Partnership Group, Center for Program Integrity, Centers for Medicare and Medicaid Services, US Department of Health and Human Services, Baltimore, MD
Introduction by Paul Silver, Practice Leader and Managing Director, Huron Consulting Group, Atlanta, GA

4:30 pm    Consolidation, Vertical Integration and Cross-Border Business: Confronting “Next Generation” Compliance Priorities
Barbara Rowland, Esq., Principal, Internal Investigations and White Collar Defense Group, Post & Schell, PC, Washington, DC
Kris Curry, MBA, Principal, Fraud Investigation & Dispute Services, Ernst & Young LLP; Former Vice President, Health Care Compliance, Pharmaceuticals Group, Johnson & Johnson, Philadelphia, PA (Moderator)

5:15 pm    Millennials and the Future of Ethics and Compliance Programs: New Technologies and Eternal Issues
Professor Ann E. Tenbrunsel, Author of Blind Spots: Why We Fail to Do What’s Right, and What We Can Do about It (with Max Bazerman);
David E. Gallo Professor of Business Ethics, University of Notre Dame; Rex and Alice A. Martin Research Director of the Institute for Ethical Business Worldwide, Notre Dame, IN
Sujata Dayal, Esq., Vice President Health Care Compliance and Privacy, Pharmaceuticals, Johnson & Johnson; Former Global Chief Compliance Officer and Corporate Vice President, Biomet, Inc., Former Member PCF Executive Committee, Chicago, IL
Amy O’Connor, MPP (Invited), Senior Director, Digital and Social Media Communications, Eli Lilly and Company, Indianapolis, IN
Jeremy Perisho, Partner and US FAS Leader, Life Sciences & Health Care, Deloitte Financial Advisory Services LLP, Boston, MA (Moderator)

Adjournement

FRIDAY, OCTOBER 23, 2015

PHARMA CONGRESS: AGENDA DAY III

INDUSTRY-ONLY COMPLIANCE

BEST PRACTICES THINK TANK (Industry-only session for pharmaceutical company compliance professionals and in-house counsel only)

8:30 am    Introduction to Day Three
Matthew D’Ambrosio, JD, MBA, Senior Vice President, Chief Compliance and Ethics Officer, Sunovion Pharmaceuticals, Inc., Marlborough, MA (Co-chair)
Gary Del Vecchio, Executive Director, US Pharmaceutical Compliance and Ethics, Bristol-Myers Squibb Company, Plainsboro, NJ (Co-chair)
Elizabeth V. Jobes, Esq., Head of Corporate Counsel and Legal Counsel, Spark Therapeutics, Philadelphia, PA (Co-chair)

Including an Update from PhRMA
Jeff Francer, Esq., Vice President and Senior Counsel, PhRMA; Former Associate Chief Counsel, Food and Drug Administration, Washington, DC
Lauren K. Roth, Esq., Assistant General Counsel, PhRMA, Washington, DC

Noon    CONGRESS ADJOURNMENT

ATTENDANCE OF CLOSED SESSION LIMITED
As noted above, attendance in the closed session is limited to company compliance professionals and in-house counsel only. The purpose of the closed session is to permit the attendees to engage in a more focused exchange of views regarding issue priority and best compliance practices. Upon registration, attendees will indicate if they plan to attend the closed session. If there is a question raised regarding qualification to attend the closed session, a member of the Congress planning committee will make the final determination.
2015 PCF PHARMA CONGRESS PLANNING COMMITTEE

Matthew D’Ambrosio, JD, MBA, Senior Vice President, Chief Compliance and Ethics Officer, Sunovion Pharmaceuticals, Inc., Marlborough, MA (Co-chair)
Gary Del Vecchio, Executive Director, US Pharmaceutical Compliance and Ethics, Bristol-Myers Squibb, Plainsboro, NJ (Co-chair)
Elizabeth V. Jobes, Esq., Head of Corporate Compliance and Legal Counsel, Spark Therapeutics, Philadelphia, PA
Timothy Ayers, JD, MPH, Vice President, Chief Compliance Officer, Horizon Pharma plc, Chicago, IL
Scott Bass, Esq., Partner and Head, Global Life Sciences Team, Sidley Austin LLP, Washington, DC
John T. Bentivoglio, Esq., Partner, Skadden Arps LLP, Washington, DC
Yogesh Bahl, CPA, MBA, Managing Director, AlixPartners, New York, NY
Andy Bender, MS, MBA, President and Founder, Polaris, New York, NY
Mary Bradley, PharmD, Healthcare Compliance Officer, Johnson & Johnson, Philadelphia, PA
Eve Costopulos, Esq., Former Vice President and Chief Ethics and Compliance Officer, Eisai Inc., Woodcliff Lake, NJ
Kris Curry, MBA, Principal, Fraud Investigation & Dispute Services, Ernst & Young LLP, Philadelphia, PA
Clive Davis, MA, JD, Vice President, Chief Compliance Officer, UCB Pharma, Atlanta, GA
Michael B. Dusseau, Vice President, Compliance Operations, Allergan plc, Parsippany, NJ
Margaret K. Feltz, MA, JD, Executive Director, Corporate Compliance, Purdue Pharma LP, Stamford, CT
Alison Fethke, Esq., Counsel, Health Care Group, Ropes & Gray, Chicago, IL
Jeffrey Fleming, Esq., Vice President Compliance North America and US Compliance Officer, Astrazeneca Pharmaceuticals LP, Wilmington, DE
Thomas M. Glavin, Vice President, Head of Compliance — US, Shire, Wayne, PA
Gary F. Giampetruzzi, Esq., Partner, Paul Hastings, New York, NY
Virginia “Ginny” A. Gibson, Esq., Partner, Hogan Lovells LLP, Philadelphia, PA
Wendy C. Goldstein, Esq., Partner, Health Care and Life Sciences Regulatory Practice, Cooley, LLP, New York, NY
Steven Guymon, Senior Compliance Advisor, Eli Lilly and Company, Indianapolis, IN
Alessandra Hawthorne, Esq., Vice President, Chief Ethics and Compliance Officer, Boehringer-Ingelheim Pharmaceuticals, Ridgefield, CT
Wendy Heckelman, PhD, President and Founder, WLH Consulting, Inc., Fort Lauderdale, FL
Erinn Hutchinson, Partner, Advisory Services, PwC, Philadelphia, PA
Margaret Jackson, MS, National Industry Marketing Director, Grant Thornton LLP, Raleigh, NC
Michael Joachim, Esq., Head of Global Corporate Compliance, Genzyme, a Sanofi Company, Cambridge, MA
Jeffrey S. Klimaski, MBA, CPA, Vice President, Global Ethics and Compliance Officer, BTG International Inc., Philadelphia, PA
Daniel A. Kracov, Esq., Partner and Head, FDA and Healthcare Practice, Arnold & Porter, Washington, DC
Terri Ledva, MS, Ethics & Compliance Leader, Iroko Pharmaceuticals, Philadelphia, PA
Beth Levine, Esq., Vice President, Associate General Counsel, Chief Compliance Officer, Regeneron, New York, NY
Christine Longawa, MA, CPA, CFE, Life Sciences Disputes, Compliance & Investigations Associate Director, Navigant Consulting, Chicago, IL
Maureen McGirr, Esq., Vice President Office of Ethics, Global Compliance Organization, Merck & Co., Inc., Philadelphia, PA
Maxine Nogard, Compliance Director, Biogen Idec, Weston, MA
John Patrick Oroho, Esq., Executive Vice President and Chief Strategy Officer, Porzio Life Sciences, LLC, Principal, Porzio, Bromberg & Newman PC, Morristown, NJ
Jeremy Perisho, Partner and US FAS Leader, Life Sciences & Health Care, Deloitte Financial Advisory Services LLP, Boston, MA
Lori Queisser, Senior Vice President and Global Chief Compliance Officer, Teva Pharmaceuticals, Horsham, PA
Kelly N. “Nikki” Reeves, MPA, JD, Partner, King & Spalding LLP, Washington, DC
Jeffrey Rosenbaum, MBA, Senior Vice President, Chief Compliance and Risk Officer, Shire; Former Chief Compliance Officer, Vertex Pharmaceuticals, Lexington, MA
Michael Shaw, Esq., Vice President and Compliance Officer, North America Pharmaceuticals & Global Franchises, GlaxoSmithKline, Philadelphia, PA
Glenna Shen, Esq., Head of Compliance, Oxyx Pharmaceuticals, South San Francisco, CA
Paul Silver, Practice Leader and Managing Director, Huron Consulting Group, Atlanta, GA
David Vance, Esq., Senior Director Business Conduct, Noven Pharmaceuticals, Inc., Miami, FL
Dr. Seth B. Whitehat, President and CEO, Whitelaw Compliance Group, LLC, West Chester, PA
Raymond Wysmierski, MBA, MJP, Associate Director, Compliance, Avanir Pharmaceuticals, Aliso Viejo, CA

2015/2016 GLOBAL PHARMA COMPLIANCE CONGRESSES
TENTH INTERNATIONAL PHARMACEUTICAL COMPLIANCE CONGRESS

May 10 – 12, 2016
Warsaw, Poland
Hilton Warsaw Hotel and Conference Center

www.InternationalPharmaCongress.com

SPONSORED BY

COSPONSORED BY

iStock Photo © 2012 udra

SAVE THE DATE!
...And Plan to Attend the SIXTH ASIA PACIFIC PHARMACEUTICAL COMPLIANCE CONGRESS AND BEST PRACTICES FORUM
Fall 2016
Watch for Details at www.AsianPharmaCongress.com
THE FOLLOWING REGISTRATION TERMS AND CONDITIONS APPLY

REGARDING WEBCAST REGISTRATIONS
1. Individuals or groups may register for Internet access. Organizations may register for group access without presenting specific registrant names. In such instances the registering organization will be presented a series of user names and passwords to distribute to participants.
2. Each registrant will receive a user name and password for access. Registrants will be able to change their user names and passwords and manage their accounts.
3. Internet registrants will enjoy six (6) months access from date of issuance of username and password.
4. Only one user (per user name and password) may view or access archived conference. It is not permissible to share user name and password with third parties. Should Internet registrants choose to access post conference content via Flash Drive, this individual use limitation applies. It is not permissible to share alternative media with third parties.
5. User name and password use will be monitored to assure compliance.
6. Each Internet registration is subject to a "bandwidth" or capacity use cap of 5 gb per user per month. When this capacity use cap is hit, the registration lapses. Said registration will be again made available at the start of the next month so long as the registration period has not lapsed and is subject to the same capacity cap.
7. For webcast registrants there will be no refunds for cancellations. Please call the Conference Office at 800-503-7419 or 206-452-5662 for further information.

REGARDING ONSITE ATTENDANCE REGISTRATION, CANCELLATIONS AND SUBSTITUTIONS
1. For onsite group registrations, full registration and credit card information is required for each registrant. List all members of groups registering concurrently on fax or scanned cover sheet.
2. For onsite registrants there will be no refunds for "no-shows" or for cancellations. You may send a substitute or switch to the webcast option. Please call the Conference Office at 800-503-7419 or 206-452-5662 for further information.

METHOD OF PAYMENT FOR TUITION
Make payment to Health Care Conference Administrators LLC by check, MasterCard, Visa or American Express. Credit card charges will be listed on your statement as payment to HealthCare (HC) Conf LLC. Checks or money orders should be made payable to Health Care Conference Administrators LLC. A $30 fee will be charged on any returned checks.

REGISTRATION OPTIONS
Registration may be made online or via mail, fax or scan. You may register through either of the following:
- Fax/Mail/Email using this printed registration form. Mail the completed form with payment to the Conference registrar at 22529 39th Ave. SE, Bothell, WA 98021, or fax the completed form to 206-319-5303, or scan and email the completed form to registration@hcconferences.com. Checks or money orders should be made payable to Health Care Conference Administrators LLC.

The following credit cards are accepted: American Express, Visa or MasterCard. Credit card charges will be listed on your statement as payment to HealthCare (HC) Conf LLC.

For registrants awaiting company check or money order, a credit card number must be given to hold registration. If payment is not received by seven days prior to the Congress, credit card payment will be processed.

TAX DEDUCTIBILITY
Expenses of training including tuition, travel, lodging and meals, incurred to maintain or improve skills in your profession may be tax deductible. Consult your tax advisor. Federal Tax ID: 91-1892021.

CANCELLATIONS/SUBSTITUTIONS
No refunds will be given for “no-shows” or for cancellations of either webcast or onsite registrations. You may send a substitute or transfer your onsite registration to a webcast registration. For more information, please call the Conference Office at 800-503-7419 or 206-452-5662.

INTELLECTUAL PROPERTY POLICY
Unauthorized sharing of Congress content via Internet access through the sharing of user names and passwords or via alternative media (Flash Drive) through the sharing of said media is restricted by law and may subject the copyright infringer to substantial civil damages. The Congress aggressively pursues copyright infringers. If a registrant needs the ability to share Congress content within his or her organization, multiple Congress registrations are available at discounted rates.

The Congress will pay a reward for information regarding unauthorized sharing of Congress content. The reward will be one quarter (25%) of any recovery resulting from a copyright infringement (less legal fees and other expenses related to the recovery) up to a maximum reward payment of $25,000. The payment will be made to the individual or individuals who in the opinion of our legal counsel first provided the factual information, which was necessary for the recovery. If you have knowledge regarding the unauthorized Congress content sharing, contact the Congress registration office.

REGISTRATION BINDING AGREEMENT
Registration (whether online or by this form) constitutes a contract and all of these terms and conditions are binding on the parties. In particular, these terms and conditions shall apply in the case of any credit/debit card dispute.

GENERAL TERMS AND CONDITIONS
Program subject to cancellation or change. If the program is cancelled the only liability of the Congress will be to refund the registration fee paid. The Congress shall have no liability regarding travel or other costs. Registration form submitted via fax, mail, email or online constitutes binding agreement between the parties.

FOR FURTHER INFORMATION
Call 800-503-7419 (Continental US, Alaska and Hawaii only) or 206-452-5662, send e-mail to registration@hcconferences.com, or visit our website at www.PharmaCongress.com.
**PHARMACEUTICAL CONGRESS**

**ATTENDANCE OF CLOSED SESSION LIMITED:** As noted on page 7, attendance in the closed session is limited to company compliance professionals and in-house counsel only. The purpose of the closed session is to permit the attendees to engage in a more focused exchange of views regarding issue priority and best compliance practices. Upon registration, attendees will indicate if they plan to attend the closed session. If there is a question raised regarding qualification to attend the closed session, a member of the Congress planning committee will make the final determination.

**COMPLETE THE FOLLOWING. PLEASE PRINT CLEARLY:**

<table>
<thead>
<tr>
<th>NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>SIGNATURE OF REGISTRANT - REQUIRED</td>
</tr>
<tr>
<td>JOB TITLE</td>
</tr>
<tr>
<td>ORGANIZATION</td>
</tr>
</tbody>
</table>

**ONSITE CONFERENCE ATTENDANCE**

**STANDARD RATES:**

**PRECONFERENCES** (Choose one):

- I: Regulatory Concepts: Basic Principles $ 495
- II: Innovations in Risk Assessment, Auditing and Monitoring $ 495
- III: Advanced Issues in Domestic and Global Transparency and Analytics $ 495
- IV: Advanced Global Compliance Issues $ 495

**CONFERENCE** (Does not include Preconference):

- Through Friday, September 4, 2015* $1,995
- Through Friday, September 25, 2015** $2,195
- After Friday, September 25, 2015 $2,395

**GROUP REGISTRATION DISCOUNT** (Does not include Preconference):

Three or more registrations submitted from the same organization at the same time receive the following discounted rates for conference registration only. To qualify, all registrations must be submitted simultaneously:

- Through Friday, September 4, 2015* each $1,795
- Through Friday, September 25, 2015** each $1,995
- After Friday, September 25, 2015 each $2,195

**PHARMACEUTICAL COMPLIANCE FORUM PCF RATES**:

- *This price reflects a discount for registration and payment received through Friday, Sept. 4, 2015.
- **This price reflects a discount for registration and payment received through Friday, Sept. 25, 2015.
- ***To qualify for the PCF member rate an individual must be a member of a member company of the Pharmaceutical Compliance Forum (PCF), www.PharmaComplianceForum.org.

**WEBCAST CONFERENCE ATTENDANCE**

**STANDARD RATES:**

**INDIVIDUAL REGISTRATION:**

- Through Friday, September 4, 2015* $ 795
- Through Friday, September 25, 2015** $ 995
- After Friday, September 25, 2015 $1,195

**SPECIAL PHARMACEUTICAL COMPLIANCE FORUM PCF RATES**:

<table>
<thead>
<tr>
<th>Preconference</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Through Friday, September 4, 2015</td>
<td>$495</td>
</tr>
<tr>
<td>Through Friday, September 25, 2015</td>
<td>$595</td>
</tr>
<tr>
<td>After Friday, September 25, 2015</td>
<td>$695</td>
</tr>
</tbody>
</table>

**GROUP REGISTRATION:**

Group registration offers the substantial volume discounts set forth below. All webcast group registrants are enrolled in the preconference and conference. Group registration permits the organizational knowledge coordinator either to share conference access with colleagues or to assign and track employee conference participation.

**CONFERENCE ELECTRONIC MEDIA:**

Websitc attendees — Following the Congress, the video and presentations are made available on a flash drive. To take advantage of the discounted price below, you must receive media WITH your Congress registration:

- Flash Drive ($129 + $15 shipping) $ 144

See INTELLECTUAL PROPERTY POLICY, page 10.

**PAYMENT**

**TOTAL FOR ALL OPTIONS, ONSITE OR WEBCAST**

Please enclose payment with your registration and return it to the Registrar at Pharma Congress, 22385 39th Ave SE, Bothell, WA 98021, or fax your credit card payment to 206-319-5303. You may also register online at www.PharmaCongress.com.

**REGISTRATION BINDING AGREEMENT**

Registration (whether online or by this form) constitutes a contract and all of these terms and conditions are binding on the parties. In particular, these terms and conditions shall apply in the case of any credit/debit card dispute. For webcast and onsite registrants there will be no refunds for “no-shows” or cancellations.

**ACCOUNT #**

**EXPIRATION DATE**

**SECURITY CODE**

**NAME OF CARDHOLDER**

**SIGNATURE OF CARDHOLDER**
THE SIXTEENTH ANNUAL
Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum

October 21 – 23, 2015
Washington, DC Mandarin Oriental
www.PharmaCongress.com

SPONSOR:
www.PharmaCongress.com

A Hybrid Conference & Internet Event

See page 2